Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
about
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cellsCurrent concepts in the management of rheumatoid arthritisImportance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts.Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts.Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MSPeptide reporters of kinase activity in whole cell lysates.A pathogenic relationship between a regulator of the actin cytoskeleton and serum response factorTyrosine kinases in inflammatory dermatologic disease.Intracellular signal pathways: potential for therapies.From desk to bed: computational simulations provide indication for rheumatoid arthritis clinical trialsActivity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads.Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.Identification of functional pathways associated with the conditional ablation of serum response factor in Dstncorn1 mice.Rheumatoid arthritis therapy: advances from bench to bedside.Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease.JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.Control of macrophage 3D migration: a therapeutic challenge to limit tissue infiltration.Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.Involvement of Src family tyrosine kinase in apoptosis of human neutrophils induced by protozoan parasite Entamoeba histolytica.Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis.A multitude of kinases--which are the best targets in treating rheumatoid arthritis?Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation.A cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis.Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses
P2860
Q21195261-FB98D1B2-FD82-4DFE-9594-AB7CE682326AQ26765124-93BF1EF0-E90E-4CE0-A7F8-91A7E2378601Q30313218-CE7F2F9F-E0AC-4366-AC41-87EAD0536F03Q33586567-D1450B55-B158-4340-81F8-4A0E83C4354EQ33672190-6E017005-F6B8-41D6-BFB0-99D527CFF840Q33699182-D61BD8B2-BE18-420F-92EC-C235A5EAF1DFQ34038376-6C8DB119-6DB3-4800-B388-64546DC86CB5Q34131490-2910071C-54F1-460A-A1F0-8F121DF6CEA9Q34166503-DF38FA38-7508-4090-91A9-82154650A569Q34551138-F387505E-2969-4E61-9879-BB3DE4768132Q34557035-91404716-0ED3-4F1E-ACAA-C4DFE81588EBQ36596379-5EE1BEF3-7AD3-4E74-98DD-3252AEFA92AFQ37492625-DA4831FB-4ACE-4C22-9781-7139C185A777Q37707758-EDAA0224-DDB1-40D5-8C42-7D4E58159C1CQ37739480-F5FE4DEF-996E-416A-A116-20712BFC888CQ37756172-3FA1107A-7FBC-491A-BEB6-7E35BD9D2A35Q38065100-DB44B02C-208B-41E9-A9DF-8E8B82FEB18DQ38260573-59035A4D-AC68-482A-A138-83AB504F6FFAQ38543700-7415BCAB-1645-491E-98D3-046A257B01ACQ39464099-153B6769-AB64-42FB-A276-2532A813033AQ40109875-EB1BC864-F472-4FD0-A887-66E57F8DA706Q40840109-B7C8A96E-62E7-4F25-956D-765CFC1ADEC9Q41948703-22A09E04-9C4D-4EFA-9263-5007C615061AQ52626728-F97D0668-1541-4153-8285-A173601C1C4AQ54544974-C839B904-E3E1-47EF-B35A-ED4CB9212ACEQ54564968-0A1B1948-89A0-47D4-9722-C538AF9DD775Q54573133-FB91FE5C-1BBE-4F2A-B5D1-121D8C58C764Q55496778-A7A4D9A8-8287-4892-8771-B5D5A06FB26AQ58234722-AC86E4A2-34C2-482E-8B45-8F5C585A346A
P2860
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
@en
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
@nl
type
label
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
@en
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
@nl
prefLabel
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
@en
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
@nl
P2093
P2860
P356
P1476
Tyrosine kinases as targets for the treatment of rheumatoid arthritis.
@en
P2093
Christina D'Aura Swanson
Ricardo T Paniagua
Tamsin M Lindstrom
William H Robinson
P2860
P2888
P304
P356
10.1038/NRRHEUM.2009.82
P407
P577
2009-06-01T00:00:00Z
P5875
P6179
1035903172